| __timestamp | ACADIA Pharmaceuticals Inc. | Alnylam Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 60602000 | 190249000 |
| Thursday, January 1, 2015 | 73869000 | 276495000 |
| Friday, January 1, 2016 | 99284000 | 382392000 |
| Sunday, January 1, 2017 | 149189000 | 390635000 |
| Monday, January 1, 2018 | 187163000 | 505420000 |
| Tuesday, January 1, 2019 | 240385000 | 655114000 |
| Wednesday, January 1, 2020 | 319130000 | 654819000 |
| Friday, January 1, 2021 | 239415000 | 792156000 |
| Saturday, January 1, 2022 | 361575000 | 883015000 |
| Sunday, January 1, 2023 | 351619000 | 1004415000 |
| Monday, January 1, 2024 | 1126232000 |
Unleashing the power of data
In the competitive world of pharmaceuticals, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Alnylam Pharmaceuticals, Inc. and ACADIA Pharmaceuticals Inc. have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, Alnylam's R&D expenses surged by over 400%, peaking at approximately $1 billion in 2023. This reflects a robust annual growth rate, underscoring their aggressive pursuit of new therapies. In contrast, ACADIA's R&D spending, while also increasing, grew at a more modest pace, with a 2023 expenditure of around $352 million, marking a 480% increase since 2014. This divergence highlights Alnylam's more aggressive investment strategy compared to ACADIA's steady approach. As these companies continue to innovate, their R&D spending patterns offer valuable insights into their future growth trajectories.
R&D Spending Showdown: Novartis AG vs ACADIA Pharmaceuticals Inc.
Research and Development: Comparing Key Metrics for Amgen Inc. and Alnylam Pharmaceuticals, Inc.
Gilead Sciences, Inc. vs ACADIA Pharmaceuticals Inc.: Strategic Focus on R&D Spending
Research and Development: Comparing Key Metrics for Regeneron Pharmaceuticals, Inc. and ACADIA Pharmaceuticals Inc.
Who Prioritizes Innovation? R&D Spending Compared for argenx SE and Alnylam Pharmaceuticals, Inc.
Analyzing R&D Budgets: Alnylam Pharmaceuticals, Inc. vs Genmab A/S
Analyzing R&D Budgets: Alnylam Pharmaceuticals, Inc. vs Bio-Techne Corporation
R&D Spending Showdown: Alnylam Pharmaceuticals, Inc. vs Ascendis Pharma A/S
Who Prioritizes Innovation? R&D Spending Compared for Viatris Inc. and ACADIA Pharmaceuticals Inc.
Analyzing R&D Budgets: Ionis Pharmaceuticals, Inc. vs ACADIA Pharmaceuticals Inc.
Research and Development Expenses Breakdown: Rhythm Pharmaceuticals, Inc. vs ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. vs Galapagos NV: Strategic Focus on R&D Spending